XML 126 R129.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Quarterly Financial Data (Unaudited) (Details Textual) (USD $) In Millions, unless otherwise specified | 12 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | ---
Dec. 31, 2012 | Dec. 31, 2013 ISIS Pharmaceuticals | Sep. 30, 2013 ISIS Pharmaceuticals | Dec. 31, 2012 ISIS Pharmaceuticals | Jun. 30, 2012 ISIS Pharmaceuticals | Mar. 31, 2012 ISIS Pharmaceuticals | Mar. 31, 2013 Hoechst | Dec. 31, 2013 Hoechst
Schedule Of Development Milestone And Collaboration [Line Items] |  |  |  |  |  |  |  |
Decrease in share of co-promotion profits due to estimated compensation damages |  |  |  |  |  |  | $ 41.5 | $ 49.7
Research and development |  | 10.0 | 75.0 | 30.0 | 12.0 | 29.0 |  |
Tax accounting correction | $ 29.0 |  |  |  |  |  |  |

X
- Definition Decrease in share of co-promotion profits due to estimated compensation damages. + References No definition available. + Details
Name: | biib_DecreaseInShareOfCoPromotionProfitsDueToEstimatedCompensationDamages
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems
Namespace Prefix: | biib_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tax accounting correction + References No definition available. + Details
Name: | biib_TaxAccountingCorrection
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration